<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461018</url>
  </required_header>
  <id_info>
    <org_study_id>IgPro20_3006</org_study_id>
    <nct_id>NCT01461018</nct_id>
  </id_info>
  <brief_title>Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)</brief_title>
  <official_title>A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects With Primary Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the long-term efficacy, tolerability, and safety of
      IgPro20 in subjects with primary immunodeficiency (PID) as an extension to the preceding
      follow-up study ZLB07_001CR (NCT01458171).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of infection episodes</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with adverse events (AEs)</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of AEs per infusion</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of clinically documented serious bacterial infections (SBIs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>SBIs are defined as bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization due to infections</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of use of antibiotics for infection prophylaxis and treatment</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median serum IgG concentration</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Primary Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>IgPro20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune globulin subcutaneous (Human)</intervention_name>
    <description>IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.</description>
    <arm_group_label>IgPro20</arm_group_label>
    <other_name>Hizentra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed the preceding follow-up study ZLB07_001CR.

          -  Written informed consent by the subject/parent/legally acceptable representative.
             Written assent for an underage subject (â‰¥7 years and &lt;20 years of age at the time of
             obtaining informed consent), according to the competencies of the subject.

        Exclusion Criteria:

          -  Pregnancy or nursing mother.

          -  Participation in a study with an investigational medicinal product (IMP) within 3
             months prior to enrollment except for study ZLB07_001CR.

          -  Subjects who are planning to donate blood during the study.

          -  Known or suspected antibodies to the IMP, or to excipients of the IMP.

          -  Treatment with another immunoglobulin G (IgG) within 3 months prior to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuke Watanabe</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Nagoya city</city>
        <state>Aichi Pref.</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Chiba city</city>
        <state>Chiba Pref.</state>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Gifu city</city>
        <state>Gifu Pref.</state>
        <zip>502-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Sapporo city</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Moriguchi city</city>
        <state>Osaka</state>
        <zip>570-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Koshigaya city</city>
        <state>Saitama Pref.</state>
        <zip>343-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Tokorozawa city</city>
        <state>Saitama Pref.</state>
        <zip>359-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo Metropolitan</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>November 25, 2014</last_update_submitted>
  <last_update_submitted_qc>November 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune globulin subcutaneous</keyword>
  <keyword>SCIG</keyword>
  <keyword>Primary immunodeficiency</keyword>
  <keyword>PID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

